Atyr PHARMA INC (NASDAQ:ATYR) Receives Consensus Rating of “Buy” from Analysts

Shares of Atyr PHARMA INC (NASDAQ:ATYR) have been assigned a consensus rating of “Buy” from the seven research firms that are covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $18.60.

ATYR has been the topic of a number of research analyst reports. Leerink Partnrs upgraded shares of Atyr PHARMA to a “strong-buy” rating in a report on Tuesday, February 18th. HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of Atyr PHARMA in a report on Tuesday, December 10th. Cantor Fitzgerald started coverage on Atyr PHARMA in a research report on Monday, January 6th. They set an “overweight” rating for the company. Finally, Leerink Partners assumed coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 target price on the stock.

Institutional Trading of Atyr PHARMA

A number of hedge funds and other institutional investors have recently modified their holdings of ATYR. JPMorgan Chase & Co. grew its stake in Atyr PHARMA by 52.0% in the third quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock valued at $55,000 after purchasing an additional 10,754 shares in the last quarter. Kingswood Wealth Advisors LLC acquired a new stake in shares of Atyr PHARMA in the 4th quarter valued at approximately $170,000. Alterna Wealth Management Inc. bought a new position in shares of Atyr PHARMA in the fourth quarter valued at $36,000. D.A. Davidson & CO. acquired a new position in Atyr PHARMA during the fourth quarter worth $141,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in Atyr PHARMA during the fourth quarter worth $144,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Atyr PHARMA Stock Performance

Shares of ATYR stock opened at $3.83 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. Atyr PHARMA has a 52 week low of $1.42 and a 52 week high of $4.66. The company’s 50 day moving average price is $3.64 and its two-hundred day moving average price is $2.90. The company has a market capitalization of $321.49 million, a P/E ratio of -4.07 and a beta of 1.10.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.